{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:32:25Z","timestamp":1764570745697},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.critrevonc.2017.12.016","type":"journal-article","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T14:18:32Z","timestamp":1514038712000},"page":"60-63","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review"],"prefix":"10.1016","volume":"122","author":[{"given":"Sebastiano","family":"Mercadante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2017.12.016_bib0005","series-title":"Breakthrough Cancer Pain Guidelines","author":"Anon","year":"2013"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pain.2003.10.002","article-title":"Is intranasal ketamine an appropriate treatment for chronic non-cancer breakthrough pain?","volume":"108","author":"Bell","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/AAP.0000000000000251","article-title":"Prospective observational study of patient-Controlled intrathecal analgesia: impact on cancer-Associated symptoms, Breakthrough pain control, and patient satisfaction","volume":"40","author":"Brogan","year":"2015","journal-title":"Reg. Anesth. Pain Med."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/0269216308089304","article-title":"Gabapentin for breakthrough pain due to bone metastases","volume":"22","author":"Caraceni","year":"2008","journal-title":"Palliat. Med."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pain.2003.07.001","article-title":"Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study","volume":"108","author":"Carr","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0030","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3747\/co.23.2865","article-title":"Canadian recommendations for the management of breakthrough cancer pain","volume":"23","author":"Daenick","year":"2006","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1191\/0269216302pm546xx","article-title":"Nitrous oxide is not beneficial for breakthrough cancer pain","volume":"16","author":"Enting","year":"2002","journal-title":"Palliat. Med."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0040","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2015.63.8221","article-title":"Randomized double-blind trial of pregabalin versus placebo in conjunction with palliative radiotherapy for cancer-induced bone pain","volume":"34","author":"Fallon","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0045","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jpainsymman.2004.03.003","article-title":"Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study","volume":"28","author":"Fisher","year":"2004","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0304-3959(03)00318-X","article-title":"Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients","volume":"106","author":"Fitzgibbon","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1533-2500.2007.00157.x","article-title":"Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet","volume":"7","author":"Freye","year":"2007","journal-title":"Pain Pract."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/jpm.2006.0163","article-title":"Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study","volume":"10","author":"Hagen","year":"2007","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0065","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/0269216310375999","article-title":"A formal feasibility study of sublingual methadone for breakthrough cancer pain","volume":"24","author":"Hagen","year":"2010","journal-title":"Palliat. Med."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0070","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/jpm.2012.0353","article-title":"Intravenous flurbiprofenaxetil to relieve cancer-related multiple breakthrough pain: a clinical study","volume":"16","author":"Hao","year":"2013","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0075","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jpainsymman.2012.09.009","article-title":"Efficacy of rapid-onset oral fentanyl formulations vs: oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials","volume":"46","author":"Jandhyala","year":"2013","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0080","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0885-3924(95)00149-2","article-title":"Patient-controlled analgesia with nitrous oxide in cancer pain","volume":"11","author":"Keating","year":"1996","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13063-016-1739-9","article-title":"A fixed inhaled nitrous oxide\/oxygen mixture as an analgesic for adult cancer patients with breakthrough pain: study protocol for a randomized controlled trial","volume":"18","author":"Liu","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0090","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1097\/j.pain.0000000000000721","article-title":"Breakthrough cancer pain: twenty-five years of study","volume":"157","author":"Mercadante","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0095","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpainsymman.2003.09.006","article-title":"Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose","volume":"27","author":"Mercadante","year":"2004","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jpain.2004.02.003","article-title":"Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain","volume":"5","author":"Mercadante","year":"2004","journal-title":"J. Pain"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jpainsymman.2005.04.014","article-title":"Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain","volume":"30","author":"Mercadante","year":"2005","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpainsymman.2006.01.013","article-title":"Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine","volume":"32","author":"Mercadante","year":"2006","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0115","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/sj.bjc.6603811","article-title":"Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthroughpain","volume":"96","author":"Mercadante","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jpainsymman.2007.04.018","article-title":"Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study","volume":"35","author":"Mercadante","year":"2008","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0125","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1470-2045(09)70350-X","article-title":"Intravenous morphine for management of cancer pain","volume":"11","author":"Mercadante","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/11597260-000000000-00000","article-title":"Pharmacotherapy for breakthrough cancer pain","volume":"72","author":"Mercadante","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0135","series-title":"NICE","author":"NICE","year":"2017"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bmjspcare-2011-000066","article-title":"Acupuncture: a treatment for breakthrough pain in cancer","volume":"1","author":"Paley","year":"2011","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0145","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.physio.2010.08.008","article-title":"Should physiotherapists use acupuncture for treating patients with cancer-induced bone pain? A discussion paper","volume":"97","author":"Paley","year":"2011","journal-title":"Physiotherapy"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0150","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0885-3924(02)00522-5","article-title":"Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer","volume":"24","author":"Pavis","year":"2002","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1067\/S1526-5900(03)00730-2","article-title":"Long term intrathecal opioid therapy with a patient-activated implanted delivery system for the treatment of refractory cancer pain","volume":"4","author":"Rauck","year":"2003","journal-title":"J. Pain"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0160","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00520-006-0131-9","article-title":"Incident pain and analgesic consumption decrease after samarium infusion: a pilot study","volume":"15","author":"Ripamonti","year":"2007","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0165","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00520-013-2036-8","article-title":"Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study","volume":"22","author":"Sousa","year":"2014","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejon.2013.11.009","article-title":"European oncology nursing society breakthrough cancer pain guidelines","volume":"18","author":"Wengstr\u00f6m","year":"2014","journal-title":"Eur. J. Oncol. Nurs."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0175","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1200\/JCO.2016.69.9504","article-title":"FentanylSublingualTablets versus subcutaneous morphine for the management of severe cancer pain episodes in patients receiving opioid treatment: a double-Blind, randomized","volume":"35","author":"Zecca","year":"2017","journal-title":"Noninferiority Trial J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.12.016_bib0180","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jpainsymman.2013.05.020","article-title":"A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes","volume":"47","author":"Zeppetella","year":"2014","journal-title":"J. Pain Symptom Manage."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817304304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817304304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T23:34:00Z","timestamp":1535153640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817304304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":36,"alternative-id":["S1040842817304304"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.12.016","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}